CAJ | 학술논문

目的：研究FITC‐NYZL1分子探针标记尿脱落细胞的特异性，探索其在诊断和监测膀胱癌的临床应用价值。方法收集2014年8月至2015年1月山西医科大学第一医院66例膀胱癌患者尿液，选取12例膀胱炎患者和24名健康人作为对照。固相合成法制备探针FITC‐NYZL1，将2 h内的新鲜尿液离心、滴片，加入探针孵育，扫描激光共聚焦显微镜（LSCM ）观察探针与细胞的结合率，同时取新鲜尿液进行瑞‐吉染色。结果 FITC‐NYZL1标记膀胱癌患者尿脱落细胞的阳性率为100％（66／66）；不同临床分期患者尿脱落细胞的结合率有差异。对照组结合率很低，实验组与对照组间差异有统计学意义（P＜0．001）。结论 FITC‐NYZL1分子探针标记结合膀胱癌细胞，特异性高，可提高膀胱癌患者尿脱落细胞的阳性率；FITC‐NYZL1在分期不同的癌细胞中结合率不同，分期越高，荧光探针特异性结合率越高。FITC‐NYZL1标记有望成为膀胱癌无创诊断和临床监测的新技术。
목적：연구FITC‐NYZL1분자탐침표기뇨탈락세포적특이성，탐색기재진단화감측방광암적림상응용개치。방법수집2014년8월지2015년1월산서의과대학제일의원66례방광암환자뇨액，선취12례방광염환자화24명건강인작위대조。고상합성법제비탐침FITC‐NYZL1，장2 h내적신선뇨액리심、적편，가입탐침부육，소묘격광공취초현미경（LSCM ）관찰탐침여세포적결합솔，동시취신선뇨액진행서‐길염색。결과 FITC‐NYZL1표기방광암환자뇨탈락세포적양성솔위100％（66／66）；불동림상분기환자뇨탈락세포적결합솔유차이。대조조결합솔흔저，실험조여대조조간차이유통계학의의（P＜0．001）。결론 FITC‐NYZL1분자탐침표기결합방광암세포，특이성고，가제고방광암환자뇨탈락세포적양성솔；FITC‐NYZL1재분기불동적암세포중결합솔불동，분기월고，형광탐침특이성결합솔월고。FITC‐NYZL1표기유망성위방광암무창진단화림상감측적신기술。
ABSTRACT:Objective To study the probe FITC‐NYZL1 targeting urine exfoliated cells and its practicality in diagnosing and monitoring bladder tumors .Methods Urine samples of 66 patients with bladder cancer hospitalized during Aug .2014 and Jan .2015 were collected ,and urine samples of 12 cystitis patients and 24 healthy people served as controls .NYZL1 was synthesized in solid state and labeled with FITC ,which formed the fluorescence molecular probe .Fresh urine was sampled within 2 hours and centrifuged .The LSCM was used to observe the combination of probe after the cells were incubated with probe .At the same time ,fresh urine was collected for Wright‐Giemsa examination .Results FITC‐NYZL1 could specifically bind to bladder cancer cells in urine ,with the positive rate being 100% (66/66) .However ,the percentage of specific binding in the control group was very low .Conclusions FITC‐CSSPIGRHC can specifically bind to bladder cancer cells .The bind rate is different in bladder cancer cells of different stage ,the higher stage ,the higher sensitivity .This suggests that FITC‐CSSPIGRHC may serve as a new technique for the noninvasive diagnosis and clinical monitoring of bladder tumor .